

Gavin J Churchyard

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4439853/gavin-j-churchyard-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

188
papers

9,639
citations

48
h-index

94
g-index

198
ext. papers

11,378
ext. citations

10.7
avg, IF

5.8
L-index

#	Paper	IF	Citations
188	Sub-Lineage Specific Phenolic Glycolipid Patterns in the Complex Lineage 1.. <i>Frontiers in Microbiology</i> , 2022 , 13, 832054	5.7	0
187	The effect of host factors on discriminatory performance of a transcriptomic signature of tuberculosis risk.. <i>EBioMedicine</i> , 2022 , 77, 103886	8.8	0
186	Prospective multicentre head-to-head validation of host blood transcriptomic biomarkers for pulmonary tuberculosis by real-time PCR.. <i>Communications Medicine</i> , 2022 , 2,		2
185	Mycobacterium tuberculosis infection, immune activation, and risk of HIV acquisition.. <i>PLoS ONE</i> , 2022 , 17, e0267729	3.7	0
184	Tuberculosis screening among ambulatory people living with HIV: a systematic review and individual participant data meta-analysis. <i>Lancet Infectious Diseases, The</i> , 2021 ,	25.5	1
183	Plasma host protein biomarkers correlating with increasing Mycobacterium tuberculosis infection activity prior to tuberculosis diagnosis in people living with HIV.. <i>EBioMedicine</i> , 2021 , 75, 103787	8.8	2
182	Causes and Outcomes of Admission and Investigation of Tuberculosis in Adults with Advanced HIV in South African Hospitals: Data from the TB Fast Track Trial. <i>American Journal of Tropical Medicine and Hygiene</i> , 2021 ,	3.2	1
181	Biomarker-guided tuberculosis preventive therapy (CORTIS): a randomised controlled trial. <i>Lancet Infectious Diseases, The</i> , 2021 , 21, 354-365	25.5	34
180	Meta-analysis of HIV-1 vaccine elicited mucosal antibodies in humans. <i>Npj Vaccines</i> , 2021 , 6, 56	9.5	4
179	Strengthening health systems to improve the value of tuberculosis diagnostics in South Africa: A cost and cost-effectiveness analysis. <i>PLoS ONE</i> , 2021 , 16, e0251547	3.7	2
178	Validation of a host blood transcriptomic biomarker for pulmonary tuberculosis in people living with HIV: a prospective diagnostic and prognostic accuracy study. <i>The Lancet Global Health</i> , 2021 , 9, e841-e853 ¹¹	13.6	11
177	Seroprevalence of -Specific IgG Antibody among Mozambican Tuberculosis Patients. <i>Journal of Fungi (Basel, Switzerland)</i> , 2021 , 7,	5.6	1
176	Adaptation of WHO® generic tuberculosis patient cost instrument for a longitudinal study in Africa. <i>Global Health Action</i> , 2021 , 14, 1865625	3	0
175	Prediction of anti-tuberculosis treatment duration based on a 22-gene transcriptomic model. <i>European Respiratory Journal</i> , 2021 , 58,	13.6	7
174	Neutrophils contribute to severity of tuberculosis pathology and recovery from lung damage pre- and post-treatment. <i>Clinical Infectious Diseases</i> , 2021 ,	11.6	2
173	Adjunctive host-directed therapies for pulmonary tuberculosis: a prospective, open-label, phase 2, randomised controlled trial. <i>Lancet Respiratory Medicine, the</i> , 2021 , 9, 897-908	35.1	15
172	Tuberculosis preventive therapy for people living with HIV: A systematic review and network meta-analysis. <i>PLoS Medicine</i> , 2021 , 18, e1003738	11.6	5

171	Predictors of silicosis and variation in prevalence across mines among employed gold miners in South Africa. <i>BMC Public Health</i> , 2020 , 20, 829	4.1	8
170	Effect of HIV Envelope Vaccination on the Subsequent Antibody Response to HIV Infection. <i>MSphere</i> , 2020 , 5,	5	3
169	Once-weekly rifapentine and isoniazid for tuberculosis prevention in patients with HIV taking dolutegravir-based antiretroviral therapy: a phase 1/2 trial. <i>Lancet HIV,the</i> , 2020 , 7, e401-e409	7.8	16
168	Algorithm-guided empirical tuberculosis treatment for people with advanced HIV (TB Fast Track): an open-label, cluster-randomised trial. <i>Lancet HIV,the</i> , 2020 , 7, e27-e37	7.8	21
167	Monitoring Anti-tuberculosis Treatment Response Using Analysis of Whole Blood Specific T Cell Activation and Functional Markers. <i>Frontiers in Immunology</i> , 2020 , 11, 572620	8.4	3
166	Impact of vaccine type on HIV-1 vaccine elicited antibody durability and B cell gene signature. <i>Scientific Reports</i> , 2020 , 10, 13031	4.9	2
165	Cost-effectiveness of a 12 country-intervention to scale up short course TB preventive therapy among people living with HIV. <i>Journal of the International AIDS Society</i> , 2020 , 23, e25629	5.4	1
164	An ecological study to evaluate the association of Bacillus Calmette-Guerin (BCG) vaccination on cases of SARS-CoV2 infection and mortality from COVID-19 2020 , 15, e0243707		
163	An ecological study to evaluate the association of Bacillus Calmette-Guerin (BCG) vaccination on cases of SARS-CoV2 infection and mortality from COVID-19 2020 , 15, e0243707		
162	An ecological study to evaluate the association of Bacillus Calmette-Guerin (BCG) vaccination on cases of SARS-CoV2 infection and mortality from COVID-19 2020 , 15, e0243707		
161	An ecological study to evaluate the association of Bacillus Calmette-Guerin (BCG) vaccination on cases of SARS-CoV2 infection and mortality from COVID-19 2020 , 15, e0243707		
160	The Lancet Respiratory Medicine Commission: 2019 update: epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant and incurable tuberculosis. <i>Lancet Respiratory Medicine,the</i> , 2019 , 7, 820-826	35.1	49
159	Effect of Xpert MTB/RIF on clinical outcomes in routine care settings: individual patient data meta-analysis. <i>The Lancet Global Health</i> , 2019 , 7, e191-e199	13.6	35
158	Controlling latent TB tuberculosis infection in high-burden countries: A neglected strategy to end TB. <i>PLoS Medicine</i> , 2019 , 16, e1002787	11.6	17
157	Building a tuberculosis-free world: The Lancet Commission on tuberculosis. <i>Lancet, The</i> , 2019 , 393, 1331-1384	13.84	158
156	Application of provincial data in mathematical modelling to inform sub-national tuberculosis program decision-making in South Africa. <i>PLoS ONE</i> , 2019 , 14, e0209320	3.7	4
155	Patient costs incurred by people living with HIV/AIDS prior to ART initiation in primary healthcare facilities in Gauteng, South Africa. <i>PLoS ONE</i> , 2019 , 14, e0210622	3.7	8
154	Heat Inactivation Renders Sputum Safe and Preserves RNA for Downstream Molecular Tests. <i>Journal of Clinical Microbiology</i> , 2019 , 57,	9.7	8

153	Guidance for Studies Evaluating the Accuracy of Sputum-Based Tests to Diagnose Tuberculosis. <i>Journal of Infectious Diseases</i> , 2019 , 220, S99-S107	7	8
152	Protein binding of rifampicin is not saturated when using high-dose rifampicin. <i>Journal of Antimicrobial Chemotherapy</i> , 2019 , 74, 986-990	5.1	8
151	TB sequel: incidence, pathogenesis and risk factors of long-term medical and social sequelae of pulmonary TB - a study protocol. <i>BMC Pulmonary Medicine</i> , 2019 , 19, 4	3.5	15
150	The Potential for Treatment Shortening With Higher Rifampicin Doses: Relating Drug Exposure to Treatment Response in Patients With Pulmonary Tuberculosis. <i>Clinical Infectious Diseases</i> , 2018 , 67, 34-41	11.6	56
149	Small contribution of gold mines to the ongoing tuberculosis epidemic in South Africa: a modeling-based study. <i>BMC Medicine</i> , 2018 , 16, 52	11.4	6
148	Cost-effectiveness of Preventive Therapy for Tuberculosis With Isoniazid and Rifapentine Versus Isoniazid Alone in High-Burden Settings. <i>Clinical Infectious Diseases</i> , 2018 , 67, 1072-1078	11.6	30
147	Pan-tuberculosis regimens: an argument for. <i>Lancet Respiratory Medicine</i> , 2018 , 6, 239-240	35.1	11
146	Using mHealth to improve tuberculosis case identification and treatment initiation in South Africa: Results from a pilot study. <i>PLoS ONE</i> , 2018 , 13, e0199687	3.7	13
145	An evaluation framework for new tests that predict progression from tuberculosis infection to clinical disease. <i>European Respiratory Journal</i> , 2018 , 52,	13.6	17
144	Empiric tuberculosis treatment in South African primary health care facilities - for whom, where, when and why: Implications for the development of tuberculosis diagnostic tests. <i>PLoS ONE</i> , 2018 , 13, e0191608	3.7	9
143	Linkage to care among adults being investigated for tuberculosis in South Africa: pilot study of a case manager intervention. <i>BMJ Open</i> , 2018 , 8, e021111	3	2
142	Immunological mechanisms of human resistance to persistent <i>Mycobacterium tuberculosis</i> infection. <i>Nature Reviews Immunology</i> , 2018 , 18, 575-589	36.5	118
141	Household point of care CD4 testing and isoniazid preventive therapy initiation in a household TB contact tracing programme in two districts of South Africa. <i>PLoS ONE</i> , 2018 , 13, e0192089	3.7	5
140	Distinct susceptibility of HIV vaccine vector-induced CD4 T cells to HIV infection. <i>PLoS Pathogens</i> , 2018 , 14, e1006888	7.6	18
139	Considerations for biomarker-targeted intervention strategies for tuberculosis disease prevention. <i>Tuberculosis</i> , 2018 , 109, 61-68	2.6	18
138	Performance of verbal autopsy methods in estimating HIV-associated mortality among adults in South Africa. <i>BMJ Global Health</i> , 2018 , 3, e000833	6.6	4
137	A stratified approach to tuberculosis treatment. <i>Nature Medicine</i> , 2018 , 24, 1639-1641	50.5	8
136	Cost-effectiveness of Xpert MTB/RIF for tuberculosis diagnosis in South Africa: a real-world cost analysis and economic evaluation. <i>The Lancet Global Health</i> , 2017 , 5, e710-e719	13.6	44

135	Strategies to Accelerate HIV Care and Antiretroviral Therapy Initiation After HIV Diagnosis: A Randomized Trial. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017 , 75, 540-547	3.1	15
134	The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. <i>Lancet Respiratory Medicine</i> , 2017 ,	35.1	313
133	The patient costs of care for those with TB and HIV: a cross-sectional study from South Africa. <i>Health Policy and Planning</i> , 2017 , 32, iv48-iv56	3.4	22
132	Measuring mortality due to HIV-associated tuberculosis among adults in South Africa: Comparing verbal autopsy, minimally-invasive autopsy, and research data. <i>PLoS ONE</i> , 2017 , 12, e0174097	3.7	18
131	High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial. <i>Lancet Infectious Diseases</i> , 2017 , 17, 39-49	25.5	199
130	Research Roadmap for Tuberculosis Transmission Science: Where Do We Go From Here and How Will We Know When We're There?. <i>Journal of Infectious Diseases</i> , 2017 , 216, S662-S668	7	11
129	What We Know About Tuberculosis Transmission: An Overview. <i>Journal of Infectious Diseases</i> , 2017 , 216, S629-S635	7	97
128	Tuberculosis Infectiousness and Host Susceptibility. <i>Journal of Infectious Diseases</i> , 2017 , 216, S636-S643	7	46
127	Impact of Targeted Tuberculosis Vaccination Among a Mining Population in South Africa: A Model-Based Study. <i>American Journal of Epidemiology</i> , 2017 , 186, 1362-1369	3.8	5
126	Priority-Setting for Novel Drug Regimens to Treat Tuberculosis: An Epidemiologic Model. <i>PLoS Medicine</i> , 2017 , 14, e1002202	11.6	15
125	A clinical scoring system to prioritise investigation for tuberculosis among adults attending HIV clinics in South Africa. <i>PLoS ONE</i> , 2017 , 12, e0181519	3.7	21
124	Outcomes of on-site antiretroviral therapy provision in a South African correctional facility. <i>International Journal of STD and AIDS</i> , 2016 , 27, 1153-1161	1.4	7
123	Tuberculosis--advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers. <i>Lancet Infectious Diseases</i> , 2016 , 16, e34-46	25.5	190
122	The timing of tuberculosis after isoniazid preventive therapy among gold miners in South Africa: a prospective cohort study. <i>BMC Medicine</i> , 2016 , 14, 45	11.4	13
121	Effect on mortality of point-of-care, urine-based lipoarabinomannan testing to guide tuberculosis treatment initiation in HIV-positive hospital inpatients: a pragmatic, parallel-group, multicountry, open-label, randomised controlled trial. <i>Lancet</i> , 2016 , 387, 1187-97	40	170
120	Household HIV Testing Uptake among Contacts of TB Patients in South Africa. <i>PLoS ONE</i> , 2016 , 11, e0155688	3.7	10
119	Diagnostic Accuracy of Lateral Flow Urine LAM Assay for TB Screening of Adults with Advanced Immunosuppression Attending Routine HIV Care in South Africa. <i>PLoS ONE</i> , 2016 , 11, e0156866	3.7	16
118	Cost-Effectiveness of Automated Digital Microscopy for Diagnosis of Active Tuberculosis. <i>PLoS ONE</i> , 2016 , 11, e0157554	3.7	8

117	Sequential Immunization with gp140 Boosts Immune Responses Primed by Modified Vaccinia Ankara or DNA in HIV-Uninfected South African Participants. <i>PLoS ONE</i> , 2016 , 11, e0161753	3.7	11
116	Verbal autopsy-assigned causes of death among adults being investigated for TB in South Africa. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2016 , 110, 510-516	2	6
115	The incidence of tuberculosis among hiv-positive individuals with high CD4 counts: implications for policy. <i>BMC Infectious Diseases</i> , 2016 , 16, 266	4	6
114	Autopsy Prevalence of Tuberculosis and Other Potentially Treatable Infections among Adults with Advanced HIV Enrolled in Out-Patient Care in South Africa. <i>PLoS ONE</i> , 2016 , 11, e0166158	3.7	34
113	Clinic-level factors influencing patient outcomes on antiretroviral therapy in primary health clinics in South Africa. <i>Aids</i> , 2016 , 30, 1099-109	3.5	8
112	Detection and Quantification of Differentially Culturable Tubercle Bacteria in Sputum from Patients with Tuberculosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016 , 194, 1532-1540	10.2	71
111	Feasibility of achieving the 2025 WHO global tuberculosis targets in South Africa, China, and India: a combined analysis of 11 mathematical models. <i>The Lancet Global Health</i> , 2016 , 4, e806-e815	13.6	99
110	Cost-effectiveness and resource implications of aggressive action on tuberculosis in China, India, and South Africa: a combined analysis of nine models. <i>The Lancet Global Health</i> , 2016 , 4, e816-e826	13.6	56
109	Using Top-down and Bottom-up Costing Approaches in LMICs: The Case for Using Both to Assess the Incremental Costs of New Technologies at Scale. <i>Health Economics (United Kingdom)</i> , 2016 , 25 Suppl 1, 53-66	2.4	53
108	The safety and immunogenicity of an adenovirus type 35-vectored TB vaccine in HIV-infected, BCG-vaccinated adults with CD4(+) T cell counts >350 cells/mm ³ . <i>Vaccine</i> , 2015 , 33, 1890-6	4.1	25
107	The relationship between Mycobacterium tuberculosis MGIT time to positivity and cfu in sputum samples demonstrates changing bacterial phenotypes potentially reflecting the impact of chemotherapy on critical sub-populations. <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 448-55	5.1	33
106	HIV-1 VACCINES. Diversion of HIV-1 vaccine-induced immunity by gp41-microbiota cross-reactive antibodies. <i>Science</i> , 2015 , 349, aab1253	33.3	144
105	Implementing a large-scale systematic tuberculosis screening program in correctional facilities in South Africa. <i>Open Forum Infectious Diseases</i> , 2015 , 2, ofu121	1	9
104	Molecular characterisation of clinical and environmental isolates of Mycobacterium kansasii isolates from South African gold mines. <i>Journal of Water and Health</i> , 2015 , 13, 190-202	2.2	8
103	Xpert MTB/RIF versus sputum microscopy as the initial diagnostic test for tuberculosis: a cluster-randomised trial embedded in South African roll-out of Xpert MTB/RIF. <i>The Lancet Global Health</i> , 2015 , 3, e450-e457	13.6	153
102	Towards host-directed therapies for tuberculosis. <i>Nature Reviews Drug Discovery</i> , 2015 , 14, 511-2	64.1	80
101	Tuberculosis active case finding: uptake and diagnostic yield among minibus drivers in urban South Africa. <i>BMC Public Health</i> , 2015 , 15, 242	4.1	2
100	Evaluation of a point-of-care tuberculosis test-and-treat algorithm on early mortality in people with HIV accessing antiretroviral therapy (TB Fast Track study): study protocol for a cluster randomised controlled trial. <i>Trials</i> , 2015 , 16, 125	2.8	12

99	Performance of a Novel Algorithm Using Automated Digital Microscopy for Diagnosing Tuberculosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015 , 191, 1443-9	10.2	22
98	Tuberculosis control in South African gold mines: mathematical modeling of a trial of community-wide isoniazid preventive therapy. <i>American Journal of Epidemiology</i> , 2015 , 181, 619-32	3.8	31
97	Brief Report: The Effect of Antiretroviral Therapy and CD4 Count on Markers of Infectiousness in HIV-Associated Tuberculosis. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015 , 70, 104-8	3.1	5
96	Regarding the effect of cured tuberculosis disease on longevity. <i>International Journal of Tuberculosis and Lung Disease</i> , 2015 , 19, 367	2.1	
95	Trends in silicosis prevalence and the healthy worker effect among gold miners in South Africa: a prevalence study with follow up of employment status. <i>BMC Public Health</i> , 2015 , 15, 1258	4.1	21
94	Clinical Relevance of Nontuberculous Mycobacteria Isolated from Sputum in a Gold Mining Workforce in South Africa: An Observational, Clinical Study. <i>BioMed Research International</i> , 2015 , 2015, 959107	3	11
93	Tuberculosis prevention in South Africa. <i>PLoS ONE</i> , 2015 , 10, e0122514	3.7	12
92	The diagnostic accuracy of urine lipoarabinomannan test for tuberculosis screening in a South African correctional facility. <i>PLoS ONE</i> , 2015 , 10, e0127956	3.7	9
91	Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized Trials. <i>PLoS ONE</i> , 2015 , 10, e0136626	3.7	15
90	Antiviral Innate Immune Activation in HIV-Infected Adults Negatively Affects H1/IC31-Induced Vaccine-Specific Memory CD4+ T Cells. <i>Vaccine Journal</i> , 2015 , 22, 688-96		7
89	Molecular epidemiology of Mycobacterium tuberculosis among South African gold miners. <i>Annals of the American Thoracic Society</i> , 2015 , 12, 12-20	4.7	11
88	The economic burden of TB diagnosis and treatment in South Africa. <i>Social Science and Medicine</i> , 2015 , 130, 42-50	5.1	86
87	The Impact of Company-Level ART Provision to a Mining Workforce in South Africa: A Cost-Benefit Analysis. <i>PLoS Medicine</i> , 2015 , 12, e1001869	11.6	11
86	Continued Follow-Up of Phambili Phase 2b Randomized HIV-1 Vaccine Trial Participants Supports Increased HIV-1 Acquisition among Vaccinated Men. <i>PLoS ONE</i> , 2015 , 10, e0137666	3.7	22
85	Missed Opportunities for TB Investigation in Primary Care Clinics in South Africa: Experience from the XTEND Trial. <i>PLoS ONE</i> , 2015 , 10, e0138149	3.7	32
84	Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study. <i>Lancet Infectious Diseases, The</i> , 2014 , 14, 388-96	25.5	80
83	Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trial. <i>Lancet, The</i> , 2014 , 383, 424-35 ⁴⁰		338
82	High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. <i>New England Journal of Medicine</i> , 2014 , 371, 1599-608	59.2	301

81	Safety, tolerability, and immunogenicity of the novel antituberculous vaccine RUTI: randomized, placebo-controlled phase II clinical trial in patients with latent tuberculosis infection. <i>PLoS ONE</i> , 2014 , 9, e89612	3.7	68
80	Tuberculosis preventive therapy: an underutilised strategy to reduce individual risk of TB and contribute to TB control. <i>South African Medical Journal</i> , 2014 , 104, 339-43	1.5	14
79	The HVTN503/Phambili HIV vaccine trial: a comparison of younger and older participants. <i>International Journal of STD and AIDS</i> , 2014 , 25, 332-40	1.4	5
78	A trial of mass isoniazid preventive therapy for tuberculosis control. <i>New England Journal of Medicine</i> , 2014 , 370, 301-10	59.2	157
77	Viral suppression following switch to second-line antiretroviral therapy: associations with nucleoside reverse transcriptase inhibitor resistance and subtherapeutic drug concentrations prior to switch. <i>Journal of Infectious Diseases</i> , 2014 , 209, 711-20	7	42
76	A trial of mass isoniazid preventive therapy for tuberculosis control. <i>New England Journal of Medicine</i> , 2014 , 370, 1662-3	59.2	11
75	Durable HIV RNA resuppression after virologic failure while remaining on a first-line regimen: a cohort study. <i>Tropical Medicine and International Health</i> , 2014 , 19, 236-9	2.3	10
74	Tuberculosis vaccines and prevention of infection. <i>Microbiology and Molecular Biology Reviews</i> , 2014 , 78, 650-71	13.2	103
73	High tuberculosis prevalence in a South African prison: the need for routine tuberculosis screening. <i>PLoS ONE</i> , 2014 , 9, e87262	3.7	43
72	Four models of HIV counseling and testing: utilization and test results in South Africa. <i>PLoS ONE</i> , 2014 , 9, e102267	3.7	36
71	Predictors of HVTN 503 MRK-AD5 HIV-1 gag/pol/nef vaccine induced immune responses. <i>PLoS ONE</i> , 2014 , 9, e103446	3.7	7
70	Incidence of HIV-associated tuberculosis among individuals taking combination antiretroviral therapy: a systematic review and meta-analysis. <i>PLoS ONE</i> , 2014 , 9, e111209	3.7	24
69	Uptake of genital mucosal sampling in HVTN 097, a phase 1b HIV vaccine trial in South Africa. <i>PLoS ONE</i> , 2014 , 9, e112303	3.7	5
68	Safety and immunogenicity of H1/IC31, an adjuvanted TB subunit vaccine, in HIV-infected adults with CD4+ lymphocyte counts greater than 350 cells/mm ³ : a phase II, multi-centre, double-blind, randomized, placebo-controlled trial. <i>PLoS ONE</i> , 2014 , 9, e114602	3.7	44
67	Comparison of laboratory costs of rapid molecular tests and conventional diagnostics for detection of tuberculosis and drug-resistant tuberculosis in South Africa. <i>BMC Infectious Diseases</i> , 2013 , 13, 352	4	39
66	The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study. <i>European Respiratory Journal</i> , 2013 , 42, 1604-13	13.6	491
65	Aspiring to zero tuberculosis deaths among southern Africa miners: is there a way forward?. <i>International Journal of Health Services</i> , 2013 , 43, 651-64	2	15
64	Mortality associated with delays between clinic entry and ART initiation in resource-limited settings: results of a transition-state model. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013 , 63, 105-11	3.1	28

63	Resistance to tenofovir-based regimens during treatment failure of subtype C HIV-1 in South Africa. <i>Antiviral Therapy</i> , 2013 , 18, 915-20	1.6	17
62	Tuberculosis: The global killer. <i>South African Journal of Science</i> , 2013 , 109, 1-2	1.3	1
61	Improved services to enrollees into an HIV rural care and treatment center in Tanzania. <i>Pan African Medical Journal</i> , 2013 , 16, 34	1.2	
60	Comparison of tenofovir, zidovudine, or stavudine as part of first-line antiretroviral therapy in a resource-limited-setting: a cohort study. <i>PLoS ONE</i> , 2013 , 8, e64459	3.7	53
59	Eligibility for isoniazid preventive therapy in South African gold mines. <i>PLoS ONE</i> , 2013 , 8, e81376	3.7	5
58	Genotype MTBDRplus for direct detection of Mycobacterium tuberculosis and drug resistance in strains from gold miners in South Africa. <i>Journal of Clinical Microbiology</i> , 2012 , 50, 1189-94	9.7	28
57	Pregnancy incidence and correlates during the HVTN 503 Phambili HIV vaccine trial conducted among South African women. <i>PLoS ONE</i> , 2012 , 7, e31387	3.7	8
56	Second-line antiretroviral therapy in a workplace and community-based treatment programme in South Africa: determinants of virological outcome. <i>PLoS ONE</i> , 2012 , 7, e36997	3.7	25
55	"Proof-of-concept" evaluation of an automated sputum smear microscopy system for tuberculosis diagnosis. <i>PLoS ONE</i> , 2012 , 7, e50173	3.7	26
54	A novel HIV treatment model using private practitioners in South Africa. <i>Sexually Transmitted Infections</i> , 2012 , 88, 136-40	2.8	15
53	Outcomes following virological failure and predictors of switching to second-line antiretroviral therapy in a South African treatment program. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012 , 61, 370-80	3.1	37
52	Undiagnosed tuberculosis among HIV clinic attendees: association with antiretroviral therapy and implications for intensified case finding, isoniazid preventive therapy, and infection control. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012 , 60, e22-8	3.1	35
51	Performance characteristics of the Cepheid Xpert MTB/RIF test in a tuberculosis prevalence survey. <i>PLoS ONE</i> , 2012 , 7, e43307	3.7	44
50	Thibela TB: design and methods of a cluster randomised trial of the effect of community-wide isoniazid preventive therapy on tuberculosis amongst gold miners in South Africa. <i>Contemporary Clinical Trials</i> , 2011 , 32, 382-92	2.3	28
49	Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study. <i>Lancet Infectious Diseases</i> , 2011 , 11, 507-15	25.5	272
48	A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204). <i>PLoS ONE</i> , 2011 , 6, e21225	3.7	120
47	Contrasting reasons for discontinuation of antiretroviral therapy in workplace and public-sector HIV programs in South Africa. <i>AIDS Patient Care and STDs</i> , 2011 , 25, 53-9	5.8	23
46	What is thwarting tuberculosis prevention in high-burden settings?. <i>New England Journal of Medicine</i> , 2011 , 365, 79-81	59.2	13

45	Twelve-monthly versus six-monthly radiological screening for active case-finding of tuberculosis: a randomised controlled trial. <i>Thorax</i> , 2011 , 66, 134-9	7.3	14
44	Diagnosing latent tuberculosis in high-risk individuals: rising to the challenge in high-burden areas. <i>Journal of Infectious Diseases</i> , 2011 , 204 Suppl 4, S1168-78	7	33
43	Changing predictors of mortality over time from cART start: implications for care. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011 , 58, 269-76	3.1	35
42	Diagnostic accuracy of a urine lipoarabinomannan enzyme-linked immunosorbent assay for screening ambulatory HIV-infected persons for tuberculosis. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011 , 58, 219-23	3.1	28
41	Development of a standardized screening rule for tuberculosis in people living with HIV in resource-constrained settings: individual participant data meta-analysis of observational studies. <i>PLoS Medicine</i> , 2011 , 8, e1000391	11.6	271
40	Cytomegalovirus viremia as a risk factor for mortality prior to antiretroviral therapy among HIV-infected gold miners in South Africa. <i>PLoS ONE</i> , 2011 , 6, e25571	3.7	32
39	Provider-initiated symptom screening for tuberculosis in Zimbabwe: diagnostic value and the effect of HIV status. <i>Bulletin of the World Health Organization</i> , 2010 , 88, 13-21	8.2	63
38	Recurrent tuberculosis: relapse, reinfection, and HIV. <i>Journal of Infectious Diseases</i> , 2010 , 201, 653-5	7	37
37	Differential specificity and immunogenicity of adenovirus type 5 neutralizing antibodies elicited by natural infection or immunization. <i>Journal of Virology</i> , 2010 , 84, 630-8	6.6	48
36	Symptom and chest radiographic screening for infectious tuberculosis prior to starting isoniazid preventive therapy: yield and proportion missed at screening. <i>Aids</i> , 2010 , 24 Suppl 5, S19-27	3.5	19
35	Adverse events with isoniazid preventive therapy: experience from a large trial. <i>Aids</i> , 2010 , 24 Suppl 5, S29-36	3.5	33
34	Barriers to implementation of isoniazid preventive therapy in HIV clinics: a qualitative study. <i>Aids</i> , 2010 , 24 Suppl 5, S45-8	3.5	60
33	Why have trials of isoniazid preventive therapy among people with HIV infection not demonstrated an effect on mortality?: did close examination of the trees obscure our view of the wood?. <i>Aids</i> , 2010 , 24 Suppl 5, S15-8	3.5	6
32	Scale-up of services and research priorities for diagnosis, management, and control of tuberculosis: a call to action. <i>Lancet, The</i> , 2010 , 375, 2179-91	4.0	91
31	Comparison of two active case-finding strategies for community-based diagnosis of symptomatic smear-positive tuberculosis and control of infectious tuberculosis in Harare, Zimbabwe (DETECTB): a cluster-randomised trial. <i>Lancet, The</i> , 2010 , 376, 1244-53	4.0	207
30	Antiretrovirals and isoniazid preventive therapy in the prevention of HIV-associated tuberculosis in settings with limited health-care resources. <i>Lancet Infectious Diseases, The</i> , 2010 , 10, 489-98	25.5	142
29	Opportunities afforded by new drugs for tuberculosis. <i>Lancet Infectious Diseases, The</i> , 2010 , 10, 368-9	25.5	2
28	Tuberculosis outcomes and drug susceptibility in individuals exposed to isoniazid preventive therapy in a high HIV prevalence setting. <i>Aids</i> , 2010 , 24, 1051-5	3.5	43

27	Team up against TB promoting involvement in Thibela TB, a trial of community-wide tuberculosis preventive therapy. <i>Aids</i> , 2010 , 24 Suppl 5, S37-44	3.5	9
26	Reducing mortality with cotrimoxazole preventive therapy at initiation of antiretroviral therapy in South Africa. <i>Aids</i> , 2010 , 24, 1709-16	3.5	28
25	Association of isoniazid preventive therapy with lower early mortality in individuals on antiretroviral therapy in a workplace programme. <i>Aids</i> , 2010 , 24 Suppl 5, S5-13	3.5	29
24	Contrasting predictors of poor antiretroviral therapy outcomes in two South African HIV programmes: a cohort study. <i>BMC Public Health</i> , 2010 , 10, 430	4.1	27
23	Low haemoglobin predicts early mortality among adults starting antiretroviral therapy in an HIV care programme in South Africa: a cohort study. <i>BMC Public Health</i> , 2010 , 10, 433	4.1	30
22	Viremia, resuppression, and time to resistance in human immunodeficiency virus (HIV) subtype C during first-line antiretroviral therapy in South Africa. <i>Clinical Infectious Diseases</i> , 2009 , 49, 1928-35	11.6	98
21	HIV suppression with stavudine 30 mg versus 40 mg in adults over 60 kg on antiretroviral therapy in South Africa. <i>Aids</i> , 2009 , 23, 1784-6	3.5	8
20	HIV infection does not affect active case finding of tuberculosis in South African gold miners. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009 , 180, 1271-8	10.2	45
19	Incidence of tuberculosis and HIV and progression of silicosis and lung function impairment among former Basotho gold miners. <i>American Journal of Industrial Medicine</i> , 2009 , 52, 901-8	2.7	33
18	The diarylquinoline TMC207 for multidrug-resistant tuberculosis. <i>New England Journal of Medicine</i> , 2009 , 360, 2397-405	59.2	613
17	HIV infection and tuberculosis in South Africa: an urgent need to escalate the public health response. <i>Lancet, The</i> , 2009 , 374, 921-33	40	349
16	Achieving the health Millennium Development Goals for South Africa: challenges and priorities. <i>Lancet, The</i> , 2009 , 374, 1023-1031	40	165
15	Expanding HIV care in Africa: making men matter in Johannesburg. <i>Lancet, The</i> , 2009 , 374, 1329	40	12
14	Advances in immunotherapy for tuberculosis treatment. <i>Clinics in Chest Medicine</i> , 2009 , 30, 769-82, ix	5.3	52
13	Epidemiology of HIV-associated tuberculosis. <i>Current Opinion in HIV and AIDS</i> , 2009 , 4, 325-33	4.2	118
12	Evaluation of the WHO criteria for antiretroviral treatment failure among adults in South Africa: authors' reply. <i>Aids</i> , 2009 , 23, 872-873	3.5	
11	"That is why I stopped the ART": patients' & providers' perspectives on barriers to and enablers of HIV treatment adherence in a South African workplace programme. <i>BMC Public Health</i> , 2008 , 8, 63	4.1	106
10	Hepatitis B virus infection and response to antiretroviral therapy (ART) in a South African ART program. <i>Clinical Infectious Diseases</i> , 2008 , 47, 1479-85	11.6	108

9	Evaluation of the WHO criteria for antiretroviral treatment failure among adults in South Africa. <i>Aids</i> , 2008 , 22, 1971-7	3.5	182
8	Risk factors for poor virological outcome at 12 months in a workplace-based antiretroviral therapy programme in South Africa: a cohort study. <i>BMC Infectious Diseases</i> , 2008 , 8, 93	4	40
7	The burden of silicosis, pulmonary tuberculosis and COPD among former Basotho goldminers. <i>American Journal of Industrial Medicine</i> , 2008 , 51, 640-7	2.7	45
6	Epidemiology of tuberculosis in a high HIV prevalence population provided with enhanced diagnosis of symptomatic disease. <i>PLoS Medicine</i> , 2007 , 4, e22	11.6	89
5	Tuberculosis preventive therapy in the era of HIV infection: overview and research priorities. <i>Journal of Infectious Diseases</i> , 2007 , 196 Suppl 1, S52-62	7	56
4	Human immunodeficiency virus and the prevalence of undiagnosed tuberculosis in African gold miners. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2004 , 170, 673-9	10.2	136
3	Morbidity and mortality in South African gold miners: impact of untreated disease due to human immunodeficiency virus. <i>Clinical Infectious Diseases</i> , 2002 , 34, 1251-8	11.6	154
2	HIV infection and silicosis: the impact of two potent risk factors on the incidence of mycobacterial disease in South African miners. <i>Aids</i> , 2000 , 14, 2759-68	3.5	122
1	Tuberculosis and HIV457-478		